⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
PT-141 (Bremelanotide) (Nasal Spray)
PT-141 (Bremelanotide) was initially studied as a nasal spray but was ultimately approved only as a subcutaneous injection. The nasal form remains investigational.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Mechanism of Action
Bremelanotide acts by activating MC3R/MC4R melanocortin receptors in the CNS. The nasal form showed signals of efficacy in a phase II trial, but development was discontinued due to cardiovascular concerns. The approved form (Vyleesi) is administered only subcutaneously.
Overview
- Nasal development was stopped due to cardiovascular concerns
- Approved only as a subcutaneous injection (Vyleesi)
- Nasal form is investigational/unapproved
- No self-compounding instructions are provided
Intranasal Delivery — Research Data
- PT-141 was initially developed as a nasal spray, but development was discontinued due to increases in blood pressure.
- It was ultimately approved as a subcutaneous injection (Vyleesi) — NOT as a nasal spray.
- The nasal form remains investigational and is not commercially available.
Investigational
The intranasal form is at an investigational stage. Available data is limited.
Dosing Table — PT-141 Nasal Spray (Investigational)
| Period | Dose | Notes |
|---|---|---|
| Phase II dose (historical) | 20 mg intranasally (discontinued development) | Historical reference only — not in active development |
Nasal development was discontinued. The approved form (Vyleesi) is administered subcutaneously at a dose of 1.75 mg. Research data only.
Formulation Notes
No self-preparation instructions provided
- There is no approved nasal formulation of PT-141.
- Self-compounding a nasal spray is not recommended.
Storage After Opening
- Not applicable — there is no approved nasal formulation.
Dosing Protocol
- The nasal form is no longer in development.
- The approved form (Vyleesi) is administered subcutaneously.
Storage Instructions
- Not applicable — there is no approved nasal formulation.
Important Notes
- The nasal form of PT-141 is not approved and is no longer in development.
- Nasal administration was discontinued due to increases in blood pressure.
- No self-compounding instructions are provided.
Benefits & Side Effects
Potential Benefits
- Efficacy in sexual dysfunction (investigational nasal form data)
Potential Side Effects
- Increased blood pressure (reason for discontinuing nasal development)
- Nausea
- Headache
- Flushing
References
Intranasal Peptide Delivery: Complete Guide
Bioavailability, absorption factors, comparison with injectables, and limitations of nasal delivery.
Research Limitations
The data on this page is strictly educational. No self-preparation or self-administration instructions are provided.
External Sources & Regulatory Status
Regulatory Approvals
Vyleesi® · HSDD (women) (2019)
FDA approved (Vyleesi®)
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →